Dermatomyositis is a form of inflammatory myopathy in which degenerative and inflammatory changes occur in the skin and the muscles. It is a rare form of acquired muscle disease that is accompanied by skin rashes. Symptoms of dermatomyositis may vary broadly from patient to patient. Deformities in the muscles may initiate with weakness and pain in the muscles of the thighs (proximal muscles), the hips, the upper arms, and the trunk. The muscles may become tender, sore, and stiff and eventually, they may express signs of degeneration (atrophy). Persons affected by dermatomyositis may experience struggle in the execution of certain tasks such as swallowing, or/and speaking, or/and climbing stairs, or/and raising their arms. Deformities in the skin often comprise typical, reddish-purple-colored, heliotrope rashes across the cheeks or on the upper portion of the eyelid (heliotrope eyelids), on the scalp and parts of the forehead, and on bridge of the nose, showing a ‘butterfly’ form of distribution. Several other distinctive rashes comprise redness and scaling of the knees, the elbows, the knuckles, or/and other expander regions (Gottron’s papules); an unusual agglomeration of fluid (edema) in body tissues nearby the eyes; or/and several other characteristics.
Symptoms of juvenile or childhood dermatomyositis are similar to those of the adult form of the disease. However, in children, the onset is generally quicker. In addition, calcification or atypical deposition of calcium in the skin and muscle tissues is common in dermatomyositis. Also, involvement of the gastrointestinal (GI) tract is more common in this condition. Moreover, in some patients with dermatomyositis, there may be a correlation to an underlying malignancy (cancer). Several researches reveal that cancer may occur following the onset of dermatomyositis. Cancer-related dermatomyositis is observed to occur more frequently in persons aged between 40 and 50 years. Though there is no characteristic cancer type or site, specialists specify that underlying cancers can most commonly grow in the testes, the ovaries, the breasts, the lungs, the GI tract, or some lymphoid tissues (in case of multiple myeloma, certain lymphomas, and leukemia) or lymphocytes (white blood cells).
According to Rare Disease Organization, the rate of incidence of dermatomyositis is estimated to be around 9.63 cases per million people globally. In children, dermatomyositis symptoms commonly occur between 5 and 15 years of age. Around three in 1,000,000 children are affected by juvenile dermatomyositis. In women, chances of dermatomyositis are two times greater than those in men. The global dermatomyositis treatment market is expanding rapidly, due to rising awareness about the disease and availability of treatments. Moreover, genetic mutations and several other factors that cause immune problems drive the global market for dermatomyositis treatment. In developing countries, unawareness about the disease restrains the market.
The global dermatomyositis treatment market can be segmented based on type of medication, distribution channel, and geography. In terms of type of medication, the market can be classified into pharmacotherapy and non-pharmacotherapy. The pharmacotherapy segment can be sub-classified into corticosteroids, immunosuppressive agents, immune globulins, and antimalarial agents. The non-pharmacotherapy segment can be sub-divided into general therapeutic measures and surgery. Based on distribution channel, the global dermatomyositis treatment market can be segregated into hospital pharmacy, retail pharmacy, and online pharmacy.
Geographically, the global dermatomyositis treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market due to advanced lifestyle and awareness among the people in the region. Development of advanced medications and diagnostic tests is a major factor driving the market in the region. The market in Asia Pacific is expected to expand at a high growth rate during the forecast period, due to presence of rapidly developing economies such as China and India in the region.
Key players operating in the global dermatomyositis treatment market include Ranbaxy Laboratories Limited, Abbott, Sanofi S.A., Cipla Inc., and Actelion Pharmaceuticals Ltd.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
The study is a source of reliable data on:
- Market segments and sub-segments
- Market trends and dynamics
- Supply and demand
- Market size
- Current trends/opportunities/challenges
- Competitive landscape
- Technological breakthroughs
- Value chain and stakeholder analysis
The regional analysis covers:
- North America (U.S. and Canada)
- Latin America (Mexico, Brazil, Peru, Chile, and others)
- Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
- Eastern Europe (Poland and Russia)
- Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
- Middle East and Africa (GCC, Southern Africa, and North Africa)
The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.
A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.
Highlights of the report:
- A complete backdrop analysis, which includes an assessment of the parent market
- Important changes in market dynamics
- Market segmentation up to the second or third level
- Historical, current, and projected size of the market from the standpoint of both value and volume
- Reporting and evaluation of recent industry developments
- Market shares and strategies of key players
- Emerging niche segments and regional markets
- An objective assessment of the trajectory of the market
- Recommendations to companies for strengthening their foothold in the market
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.